UCB (EBR:UCB) UCB Media Room: General Meeting of Shareholders 2024

Transparency directive : regulatory news

25/04/2024 18:00

https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r= CyBv9bezcPT-2BuItTLKIHepbxTbo-2FYbVFPSBekB-2Bmk9X7Kl8shoTE6BsSbYYjHYcOVCrOC= rjYrJUHPDVbu1NKaBE-3D-PEb_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2= FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLN= n-2B6FohpNoV33LRaEyf0mqf17xp6pekr8So7QYtu3-2FdIMO4RVZQjZ5My948U2-2B61xp-2Fx= iQJcKqqFG5y07R6jIoVvlZB3RVDVoYHP-2BVdj0ta3CQoVZmkFE7n-2FVUVHjdkS5qE6Qmc5-2F= je09XTRCfpmv80fvszVsX6vJfl0SPPYJhyFtdsEi74HCHCNVv4a07HTCtJbzIsbsPeCsmD3XaFF= Jzhxnbb-2BwEkhReOi9-2B-2FnSbpMSyr2YKx83ZVk-3D ** UCB=E2=80=99s General Meeting of Shareholders 2024 ------------------------------------------------------------ =C2=B7 For financial year 2023: Gross dividend of =E2=82=AC 1.36 per share = (+ 2,26%), payable 30 May 2024 =C2=B7 All agenda items put to vote approved =C2=B7 UCB=E2=80=99s Board of Directors composed by a majority of independe= nt directors=C2=A0 =C2=B7 The message of Jean-Christophe Tellier, CEO of UCB is available on U= CB=E2=80=99s global corporate website Brussels (Belgium), 25 April 2024 =E2=80=93 18:00 (CEST) (regulated informa= tion) =E2=80=93 Today, UCB held its Annual General Meeting of Shareholders = (AGM) directly followed by an Extraordinary General Meeting of the Sharehol= ders (EGM). The Company offered the choice to UCB shareholders to either pa= rticipate in-person or to cast their vote by proxy. At the AGM [154 502 563= ] shares (81,11% of shares entitled to vote) were represented. At the EGM, = [152.708.839] shares were represented (80,17% of shares entitled to vote). The message of Mr. Jean-Christophe Tellier, Chief Executive Officer of UCB,= published at the occasion of this general meeting, is available on the UCB= website (https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo= 7XKIuSly0rC2gh0pAj0jRFBrcUOJMNg4G4Or8ULqxfOhO2qoHb5I5NfNpL7tQOe1oo63P9y4Wua= ruvoRNtLMkewApLQxCO-2BWafwjw39nycKZ2k9TGDYbrN8_Uj_2dCLUNbuBjhX746-2FvM63L9H= yn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO9= 3DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33LRaEyf0mqf17xp6pekr8So7QYtu3-2FdIMO4R= VZQjZ5My948U2-2B61xp-2FxiQJcKqqFG5y07R6jIoVvlZB3RVDVoYHYRpQHU7Fatbad0bW3HP3= na18WL87tFln-2B4XHMFK5leTAyRcRaj-2Be3reWGSk-2BawJKqPnyqVtUqsmLOdNpnGjueTP5h= L4IqJDtF8t7UistX4OIwTbobLiQ7ppvDLmH8VoaQZmEgxY0geX-2FUSXhHt3E0-3D . During his speech, Mr. Tellier commented: =E2=80=9CToday, I=E2=80=99m pleas= ed to stand in front of you and talk about the unique new phase we=E2=80=99= ve begun. With 14 major regulatory approvals for UCB medicines across six p= atient populations and three continents, we are now able to provide more, n= ew and differentiated treatment options for people living with severe disea= ses.=E2=80=9D During his speech, Jean-Christophe Tellier also spoke about t= he company=E2=80=99s bright future: =E2=80=9CUCB is poised for a decade plu= s of growth, driven by our dedicated employees and commitment to creating v= alue for patients and society. Looking ahead, we're confident in our five g= rowth drivers: EVENITY^=C2=AE, FINTEPLA^=C2=AE=E2=96=BC, BIMZELX^=C2=AE, RY= STIGGO^=C2=AE, and ZILBRYSQ^=C2=AE. These medicines, coupled with our robus= t innovation efforts, form the backbone of our growth strategy.=E2=80=9D=C2= =A0 The AGM approved for the fiscal year 2023 the payment of a gross dividend o= f =E2=82=AC 1.36 per share (net dividend of =E2=82=AC 0.952 per share) comp= ared to =E2=82=AC 1.33 per share for 2022 (net =E2=82=AC 0.931). The ex-div= idend date is 26 April 2024, the dividend (coupon no. 27) will be payable a= s of 30 April 2024. During the AGM, three Board mandates renewals were approved: (i) the mandat= es of Pierre Gurdjian and Ulf Wiinberg were renewed as independent director= s for a term of 4 years and they will both continue to be members of the Go= vernance, Nomination and Compensation Committee (GNCC). (ii) the mandate of= Charles-Antoine Janssen was also renewed as director for a term of 4 years= and he will continue to be a member of the GNCC too. He has also replaced = Fiona du Monceau as Vice-Chair of the Board, as she stepped down from the B= oard to take on an Executive Committee role within UCB. During the AGM, Mrs= . Fiona was thanked for her contribution to the Board which illustrated her= dedication to people and society, her leadership and strong business acume= n.=C2=A0 Bert De Graeve stepped down from the Board of Directors of UCB at the occas= ion of this AGM. after a 14-year service in the Board of UCB. During his sp= eech, Jean-Christophe Tellier expressed his deepest appreciation for Bert D= e Graeve=E2=80=99s remarkable service and invaluable contributions during h= is tenure on the Board. The Annual General Meeting of UCB also approved the appointment of the foll= owing 3 new independent Board Members, each one for a term of 4 years: (i) = Nefertiti Greene, also joining the GNCC (ii) Dolca Thomas, becoming member = of the Scientific Committee and (iii) Rodolfo Savitzky, also becoming membe= r and chair of the Audit Committee. =C2=A0 UCB=E2=80=99s Board of Director continues to be composed of a majority of i= ndependent directors (10 out of 14 members or 71% independent members, in c= omparison to 54% at 31 December 2023). The Audit Committee and the Governan= ce, Nomination and Compensation Committee will be chaired by independent di= rectors, respectively Rodolfo Savitzky and Kay Davies. From a gender divers= ity perspective, the Board will be composed of 6 women and 8 men (43% in co= mparison to 38% at 31 December 2023). For the curriculum vitae of the Board members, please visit the UCB website= : https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly= 0rC2gh0pAj0jRFBrcUOJMNg4E0IunWKPW1RKzxxbPvyYwu4-2BGROe9nsSDxTo8-2FUU7ZDg-3D= -3DUcu-_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ= 0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33LRaE= yf0mqf17xp6pekr8So7QYtu3-2FdIMO4RVZQjZ5My948U2-2B61xp-2FxiQJcKqqFG5y07R6jIo= VvlZB3RVDVoYPVQix-2B6tdD1h-2BY-2B99IUtJjwB6ursXhLIYDSE0HSZwwBlqGucJrbTxtXdC= ss3g-2F9vTan65x79U9gR0EnPeINyFWlfF-2Bi8YXhxlx6SH1VvGEH-2FND27xVwAECUwis6vAk= p6iJ1RZGlq7-2FrOUt72QuewXk-3D (https://u7061146.ct.sendgrid.net/ls/click?up= n=3Du001.gqh-2BaxUzlo7XKIuSly0rC2gh0pAj0jRFBrcUOJMNg4E0IunWKPW1RKzxxbPvyYwu= Dh9cEwZ6z77lyFQcnlayVg-3D-3D-CFi_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCj= ZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33Sbk= EZvEGLNn-2B6FohpNoV33LRaEyf0mqf17xp6pekr8So7QYtu3-2FdIMO4RVZQjZ5My948U2-2B6= 1xp-2FxiQJcKqqFG5y07R6jIoVvlZB3RVDVoYM0PnEK2S4XCUKhXVsey3ERhz3fxFWlDKrg-2F9= A3QnaKUjuITsswvIoTVYUodxowAnONGsVIR6WpXHwF4Y2fRwOvhm0LU-2BzssNTJ9-2FwIxRAUH= Wd8VS-2BYyaec-2BC-2BubrnCHFNQfCBuQsXilv66YeGwKNhM-3D .=C2=A0 All other agenda items put to vote at the AGM and EGM were approved by the = shareholders. More information including details of the votes will be avail= able soon on UCB's website (https://u7061146.ct.sendgrid.net/ls/click?upn= =3Du001.gqh-2BaxUzlo7XKIuSly0rC2gh0pAj0jRFBrcUOJMNg4G4Or8ULqxfOhO2qoHb5I5Nf= NpL7tQOe1oo63P9y4WuavfjbzuJLFRB7lq0CIfxhlcxfOQILOjI-2FfdGxbcnfWxEYJFy_2dCLU= NbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6= ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33LRaEyf0mqf17xp6pe= kr8So7QYtu3-2FdIMO4RVZQjZ5My948U2-2B61xp-2FxiQJcKqqFG5y07R6jIoVvlZB3RVDVoYG= kr4mKP2r-2FRoUsNK5-2B0TE1wenE6ukvqkCh-2BYYePw5ZiNW4Waid3Xmy3I2HeN-2FG3UcgDY= SQsxeOq-2F9EDsUxBDzf1-2Fau8M3v-2BxE-2F9GUZ4daT3dfuf-2FBKQ81akbWM8pMP1Aak8r1= CeUaNyBuy1Kg37ntQ-3D . The Integrated Annual Report 2023 of UCB can be downloaded on UCB's website= at https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuS= ly0rC2gh0pAj0jRFBrcUOJMNg4FZAZJZrp83BD0VGJjVPkMQT2oy8rWcWZHGz0c-2BYa5XXw-3D= -3DVerN_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ= 0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33LRaE= yf0mqf17xp6pekr8So7QYtu3-2FdIMO4RVZQjZ5My948U2-2B61xp-2FxiQJcKqqFG5y07R6jIo= VvlZB3RVDVoYO8dgKcX33By-2BkTjWO6astuek9kc2T759THerIs0gi4hV1uGqc80M-2B17CZHI= ZU0FwitBj-2BJxkV52X8yNzpG8wrRvosMFwmHWOUZ7cQ-2FAcEee6LAR-2FhrMs9QM-2B4rbNUw= zzORqZoeWZS7rxzPWhNLQ7So-3D or is available on the online portal at https:/= /u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCz9eqdO= Vgsosw7ayZf6jIINTtG4Aij-2F0-2BZ7d0fUCtDT53cyv_2dCLUNbuBjhX746-2FvM63L9Hyn3K= nTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93Dwf= Ixs8cV3s33SbkEZvEGLNn-2B6FohpNoV33LRaEyf0mqf17xp6pekr8So7QYtu3-2FdIMO4RVZQj= Z5My948U2-2B61xp-2FxiQJcKqqFG5y07R6jIoVvlZB3RVDVoYBK6RMdACCydI12mnL8o-2Ff8I= N8hXSZL2dm1OdAlZ7vNrcsmyTBQIk7vF5xr-2B9uIIL6NAOxz7n8V8t29eHBPMK-2BqvrzhbYuE= yDuABGzp-2FRZORxEujRw3ujsF3IiBwPbPvgS-2FyMbtNDbMpd74ZgyZtcIw-3D The financial results for the first half year 2024 will be published on 25 = July 2024.=C2=A0 Next year's General Meeting will be held on 24 April 2025. For further information, contact UCB:=C2=A0 Investor Relations Antje Witte Investor Relations, UCB T +32.2.559.9414 Global Communications=C2=A0 Laurent Schots Media Relations, UCB T+32.2.559.9264 Laurent.schots@ucb.com=C2=A0 About UCB=C2=A0 UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With approximately 9,000 peopl= e in approximately 40 countries, the company generated revenue of =E2=82=AC= 5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Foll= ow us on Twitter: @UCB_news. Forward looking statement This document contains forward-looking statements, including, without limit= ation, statements containing the words =E2=80=9Cpotential=E2=80=9D, =E2=80= =9Cbelieves=E2=80=9D, =E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80= =9D, =E2=80=9Cintends=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2= =80=9D, =E2=80=9Cestimates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill= =E2=80=9D, =E2=80=9Ccontinue=E2=80=9D and similar expressions. These forwar= d-looking statements are based on current plans, estimates and beliefs of m= anagement. All statements, other than statements of historical facts, are s= tatements that could be deemed forward-looking statements, including estima= tes of revenues, operating margins, capital expenditures, cash, other finan= cial information, expected legal, arbitration, political, regulatory or cli= nical results or practices and other such estimates and results. By their n= ature, such forward-looking statements are not guaranteeing future performa= nce and are subject to known and unknown risks, uncertainties, and assumpti= ons which might cause the actual results, financial condition, performance = or achievements of UCB, or industry results, to be materially different fro= m any future results, performance, or achievements expressed or implied by = such forward-looking statements contained in this document.=C2=A0 Important factors that could result in such differences include but are not= limited to: global spread and impacts of wars and pandemics, changes in ge= neral economic, business and competitive conditions, the inability to obtai= n necessary regulatory approvals or to obtain them on acceptable terms or w= ithin expected timing, costs associated with research and development, chan= ges in the prospects for products in the pipeline or under development by U= CB, effects of future judicial decisions or governmental investigations, sa= fety, quality, data integrity or manufacturing issues; potential or actual = data security and data privacy breaches, or disruptions of our information = technology systems, product liability claims, challenges to patent protecti= on for products or product candidates, competition from other products incl= uding biosimilars, changes in laws or regulations, exchange rate fluctuatio= ns, changes or uncertainties in tax laws or the administration of such laws= , and hiring and retention of its employees. There is no guarantee that new= product candidates will be discovered or identified in the pipeline, or th= at new indications for existing products will be developed and approved. Mo= vement from concept to commercial product is uncertain; preclinical results= do not guarantee safety and efficacy of product candidates in humans. So f= ar, the complexity of the human body cannot be reproduced in computer model= s, cell culture systems or animal models. The length of the timing to compl= ete clinical trials and to get regulatory approval for product marketing ha= s varied in the past and UCB expects similar unpredictability going forward= . Products or potential products which are the subject of partnerships, joi= nt ventures or licensing collaborations may be subject to disputes between = the partners or may prove to be not as safe, effective or commercially succ= essful as UCB may have believed at the start of such partnership. UCB=E2=80= =99s efforts to acquire other products or companies and to integrate the op= erations of such acquired companies may not be as successful as UCB may hav= e believed at the moment of acquisition. Also, UCB or others could discover= safety, side effects or manufacturing problems with its products and/or de= vices after they are marketed. The discovery of significant problems with a= product similar to one of UCB=E2=80=99s products that implicate an entire = class of products may have a material adverse effect on sales of the entire= class of affected products. Moreover, sales may be impacted by internation= al and domestic trends toward managed care and health care cost containment= , including pricing pressure, political and public scrutiny, customer and p= rescriber patterns or practices, and the reimbursement policies imposed by = third-party payers as well as legislation affecting biopharmaceutical prici= ng and reimbursement activities and outcomes. Finally, a breakdown, cyberat= tack or information security breach could compromise the confidentiality, i= ntegrity and availability of UCB=E2=80=99s data and systems. Given these uncertainties, you are cautioned not to place any undue relianc= e on such forward-looking statements. These forward-looking statements are = made only as of the date of this document, and do not reflect any potential= impacts from the evolving conflicts, wars, pandemics, as well as any other= adversity, unless indicated otherwise. The company continues to follow the= development diligently to assess the financial significance of these event= s, as the case may be, to UCB. UCB expressly disclaims any obligation or duty to update any forward-lookin= g statements in this document, either to confirm the actual results or to r= eport or reflect any change in its forward-looking statements with regard t= hereto or any change in events, conditions or circumstances on which any su= ch statement is based, unless such statement is required pursuant to applic= able laws and regulations. GenericFile UCB PR Update April 25 2024 ENG (https://u7061146.ct.sendgrid.net/ls/click?= upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepZ6lk3CbPEPYgc1Z7ks= 7yN3WjloHRwv5-2FsMP4lIFWPJrEc5Oms9kWO9Wclb-2FoHnFQ0-3DHAZG_2dCLUNbuBjhX746-= 2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia= 3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33LRaEyf0mqf17xp6pekr8So7QYtu3= -2FdIMO4RVZQjZ5My948U2-2B61xp-2FxiQJcKqqFG5y07R6jIoVvlZB3RVDVoYFmTo5yFU2LXX= udzVjF8rB-2BIRUpvh4-2F8hJiOSnzQKfkxZbiEZ4AGPvBTEjxIr6-2FtJxoNCFQDhyJMquEGEM= BC4xwyTfhWQNcv3EM9-2BPx0kdSwrMQimMElHNafAU-2BKRcmg3rWozJUc5kXU55rRexF0Cgg-3= D ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIu= Sly0rC3nfmD42E6tJ6HwHGmqtXbhtXDlQ2cTEdRpWV-2BrYPIUNgMNpCQqqGiIX7zJUK-2FHLZN= 2gg1x64-2B0eeWqj8fP7aol3DP04WSGF8AQH66zeg0-2BOIPGdRLh8KJrTGd9-2BXIQvnZGd6EH= xapBYCeFIFsmnYPI-3DBQfg_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FK= l1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-= 2B6FohpNoV33LRaEyf0mqf17xp6pekr8So7QYtu3-2FdIMO4RVZQjZ5My948U2-2B61xp-2FxiQ= JcKqqFG5y07R6jIoVvlZB3RVDVoYOHnYUmjxELnM1yaga3yhlTa7JtzGSjbTmJUKvkYXJYo1gpU= DfpxrlZlnERCpDfITzdZm08rN0-2FODiA2DxwBsB0h8dWGdZW-2BIa9MMFb3woEpGdnzNkAtdpf= 9SWlD9FFrO65AEivzfnDv-2Fk-2B9zhc4ZNA-3D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium

UCB's latest news

26/04/2024 20:00

UCB (EBR:UCB) UCB Media Room: General Meeting of Shareholders 2024

Transparency directive : regulatory news

UCB's latest news

Other stories